Nanovis announces the formation of a Scientific Advisory Board to advance the FDA-designated nanotechnology surface
The formation of the board comes at a pivotal time for Nanovis as they continue their ongoing mission to leverage nanotechnology for improved patient care.
COLUMBIA CITY, Ind., Nov. 2, 2023 /PRNewswire-PRWeb/ — Nanovis, a leader in nanotechnology surface solutions for orthopedic, spinal and dental applications, announces the formation of its Scientific Advisory Board (SAB). The board will consist of Dr. C. Lowry Barnes, Dr. Douglas W. Pahl, Dr. Brent Ponce and Dr. Thomas J. Webster. This team is a multidisciplinary, multidisciplinary scientific advisory board composed of leaders from the musculoskeletal specialties. Nanovis will continue to fill their SAB with other specialties such as dentistry, trauma, foot and ankle, and infectious diseases in the coming months.
Brian More, CEO of Nanovis, said: “The creation of the SAB marks a pivotal moment for Nanovis in our ongoing mission to leverage nanotechnology for improved patient care. The board’s collective expertise will be critical in advancing claims and indications for nanoVIS Ti Surface Technology, our FDA-designated nanotechnology surface that has been approved for seven product systems and has been successfully implanted in thousands of patients.”
In addition to technological advancements, the SAB will play a critical role in guiding Nanovis’ approach to clinical data collection and analysis. Their expertise will help strategically collect clinical data, ensure its thorough research and help present the benefits of Nanovis’ technologies at conferences and in academic journals. This initiative aims to validate the clinical efficacy of the company’s surface technology portfolio, drive innovation, discover new product applications and identify potential new markets.
Brian More added: “With the guidance of the SAB, we are well positioned to break new ground in orthopedic implant technology, ensuring that our scientific breakthroughs translate into real benefits for surgeons and patients.”
Board members:
Dr. C. Lowry Barnes
Orthopedic surgeon
University of Arkansas, Little Rock, Chairman of the Department of Orthopedic Surgery, Hip & Knee Specialty
Dr. Douglas W. Pahl
Orthopedic surgeon
Hughston Spine and the Hughston Clinic Spine specialty
Dr. Brent Ponce
Orthopedic surgeon
Hughston Clinic, Columbus, Georgia
Chair, Hughston Foundation Research Shoulder and Sports Medicine Specialty
Dr. Thomas J. Webster
Professor
Brown University
Department of Pre-college and Undergraduate Studies
Nanovis will exhibit its FDA-designated nanotechnology surface at the American Association of Hip and Knee Surgeons in Dallas, Texas, November 2-5, 2023. In conjunction with the AAHKS meeting, Scientific Advisory Board Member Dr. C. Lowry Barnes to host a Nanovis-sponsored educational event on nanotechnology in total joint arthroplasty.
About Nanovis
Nanovis is a technology-driven company committed to discovering unmet clinical needs, developing innovative and enabling solutions, and validating new technologies for clinical and market acceptance. The company, through its subsidiary Nanovis Spine, has successfully commercialized its proprietary nanoVIS Ti Surface Technology™ for a range of spinal implants, including the nano FortiFix™ Pedicle screws and Nano FortiCore™ PEEK Titanium Hybrid Interbodies, the latter being enriched with OsteoSync™ technology licensed from Site Medical.
In particular, the nanoVIS Ti Surface technology™ platform shows in preclinical studies its potential to evolve into an antimicrobial surface in select markets, while Nanovis simultaneously innovates a next-generation antimicrobial technology aimed at combating localized infections in various applications including skin, transcutaneous devices and orthopedic implants .
Ready to learn more about the science behind nanoVIS Ti Surface Technology™? Join us on LinkedIn.
Media contact
Guillaume Viallaneix, Nanovis, 1 (407) 960-2994, guillaume@medtechmomentum.com, MedTechMomentum.com
SOURCE Nanovis
